McDERMOTT WILL & EMERY LLP, WILLIAM G. GAEDE, III (136184), JUDITH S.H. HOM (203482), Menlo Park, CA, Attorneys for Geron Corporation.
BARTKO, ZANKEL, BUNZEL & MILLER, Benjamin K. Riley (112007), Jayne Laiprasert (256930), San Francisco, California.
ROTHWELL, FIGG, ERNST & MANBECK, P.C., R. Danny Huntington (pro hac vice), Sharon E. Crane (pro hac vice), Seth E. Cockrum (pro hac vice), Washington, D.C., Attorneys for ViaCyte, Inc.
ORDER GRANTING STIPULATED REQUEST TO ENLARGE TIME PURSUANT TO CIVIL L.R. 6-2
WILLIAM H. ORRICK, District Judge.
WHEREAS, on September 13, 2012, Plaintiff Geron Corporation ("Geron" or "Plaintiff") filed the complaint in this action against Defendant ViaCyte, Inc. ("ViaCyte" or "Defendant") pursuant to 35 U.S.C. § 146 (D.I. 1);
WHEREAS, on January 3, 2013, a Case Management Conference was held in this case before Judge Edward M. Chen and the Court ordered that mediation was to be completed by June 30, 2013, that Defendant was to file a motion to define the scope of the case and discovery by February 21, 2013, that Plaintiff was to file its opposition by March 7, 2013, that Defendant was to file its reply by March 14, 2013, that discovery is limited to written discovery focused on those issues which were decided by the Patent Appeals Board, and that hearing on the preceding motion and a further Case Management Conference was set for April 4, 2013 (D.I. 31);
WHEREAS, on January 7, 2013, Geron publicly announced that it had entered into an Asset Contribution Agreement, dated January 4, 2013, with BioTime, Inc. and BioTime Acquisition Corporation, now Asterias Biotherapeutics, Inc. ("Asterias"), providing for the divestiture of certain Geron stem cell assets, including the intellectual property at issue in this 35 U.S.C. § 146 appeal, to Asterias (the "Transaction") upon the closing of the Transaction;
WHEREAS, under the Asset Contribution Agreement, the closing of the Transaction is contemplated to occur on or about September 30, 2013. Conditions to the closing include the requirement that Asterias and BioTime seek to obtain the effectiveness of certain registration statements filed by each of them. The effectiveness of such registration statements is subject to review and approval by the United States Securities and Exchange Commission (the "SEC"), and none of Asterias, BioTime, or Geron controls the timing or course of SEC review or approval;
WHEREAS, upon the closing of the Transaction, Asterias will substitute in as plaintiff in this action as the owner of the Geron intellectual property at issue in this action. Further, under the Asset Contribution Agreement, Geron may not settle this action without Asterias' consent. Accordingly, the parties have conferred and are interested in conducting settlement discussions before a mediator through the Court's Alternative Dispute Resolution procedures between Defendant ViaCyte, Inc. and Asterias, upon the closing of the Transaction;
WHEREAS, prior to reassignment of this case to the undersigned, counsel met, conferred and agreed that dates for mediation, Motion to Define the Scope of this Case and Discovery, Opposition to the Motion to Define the Scope, Reply to the Motion to Define the Scope, and the Case Management Conference be extended until the earlier of (a) 30 days after the close of the Transaction or (b) 31 days after September 30, 2013, as follows:
Event Dates Motion to Define Scope October 31, 2013 Opposition to Motion to Define Scope November 14, 2013 Reply to Motion to Define Scope November 21, 2013 Case Management Conference December 5, 2013 Mediation Completion (ADR L.R. 6-3) February 28, 2014
WHEREAS, the parties had jointly filed a Stipulated Request for Order Enlarging Time Pursuant to Civ. L.R. 6-2 (D.I. 32) on January 16, 2013, and Judge Edward M. Chen ...